- Home
- CGTX vs ALGS Comparison
CGTX vs ALGS Comparison
Compare CGTX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- ALGS
- Stock Information
- Founded
- CGTX 2007
- ALGS 2018
- Country
- CGTX United States
- ALGS United States
- Employees
- CGTX N/A
- ALGS N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- ALGS Health Care
- Exchange
- CGTX Nasdaq
- ALGS Nasdaq
- Market Cap
- CGTX 53.4M
- ALGS 53.0M
- IPO Year
- CGTX 2021
- ALGS 2020
- Fundamental
- Price
- CGTX $1.54
- ALGS $7.70
- Analyst Decision
- CGTX Strong Buy
- ALGS Strong Buy
- Analyst Count
- CGTX 3
- ALGS 1
- Target Price
- CGTX $2.83
- ALGS $70.00
- AVG Volume (30 Days)
- CGTX 8.5M
- ALGS 62.6K
- Earning Date
- CGTX 08-07-2025
- ALGS 08-06-2025
- Dividend Yield
- CGTX N/A
- ALGS N/A
- EPS Growth
- CGTX N/A
- ALGS N/A
- EPS
- CGTX N/A
- ALGS N/A
- Revenue
- CGTX N/A
- ALGS $3,174,000.00
- Revenue This Year
- CGTX N/A
- ALGS N/A
- Revenue Next Year
- CGTX N/A
- ALGS $51.55
- P/E Ratio
- CGTX N/A
- ALGS N/A
- Revenue Growth
- CGTX N/A
- ALGS N/A
- 52 Week Low
- CGTX $0.22
- ALGS $3.76
- 52 Week High
- CGTX $1.97
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- CGTX 77.80
- ALGS 46.70
- Support Level
- CGTX $1.15
- ALGS $7.31
- Resistance Level
- CGTX $0.74
- ALGS $7.85
- Average True Range (ATR)
- CGTX 0.19
- ALGS 0.75
- MACD
- CGTX 0.09
- ALGS -0.09
- Stochastic Oscillator
- CGTX 69.59
- ALGS 35.03
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.